Metastatic Colorectal Cancer: Recommendations for Evaluation and Management

PROGRAM DESCRIPTION Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS ...

PROGRAM DESCRIPTION
Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will examine optimal management of metastatic colorectal cancer.

EDUCATIONAL OBJECTIVES
Upon completion of this educational activity, participants should be able to:Discuss the clinical relevance of extended RAS analysis at diagnosis and first relapse, BRAF testing, and MSI testing during workup for mCRC patientsApply the most current evidence-based clinical practice guidelines to the management of patients with mCRCDescribe a multidisciplinary team approach to the management of mCRC involving surgery, radiation, and other treatment modalitiesReview efficacy and safety data from clinical trials of approved agents being investigated for new indications in mCRC and for emerging investigational agents for the management of mCRC

---

Write the first review

Resource tags